Ginès A, Planas R, Angeli P, Guarner C, Salerno F, Ginès P, Saló J, Rodriguez N, Domènech E, Soriano G
Department of Medicine, Hospital Clínic i Provincial, Barcelona, Spain.
Hepatology. 1995 Jul;22(1):124-31. doi: 10.1002/hep.1840220120.
It has recently been suggested that insertion of a titanium tip at the venous end of the LeVeen shunt drastically reduces the rate of shunt obstruction. To assess whether the LeVeen shunt with titanium tip improves the results obtained with therapeutic paracentesis, 81 patients with cirrhosis and refractory ascites were randomly assigned to therapy with paracentesis plus intravenous albumin (42 patients) or LeVeen shunt with titanium tip (39 patients). If patients were readmitted for ascites during follow-up, those in the first group were treated with paracentesis, and those in the LeVeen shunt group by the insertion of a new valve or a new shunt if obstruction was demonstrated. During first hospitalization, both treatments were equally effective in removing ascites. Complications were similar in both groups except for a higher rate of severe bacterial infection in the LeVeen shunt group. The mean duration of hospitalization was shorter in the paracentesis group than in the shunt group. During follow-up, the total number of readmissions and the number of readmissions for ascites were higher in the paracentesis group than in the shunt group (252 vs. 99, P < .001; and 193 vs. 43, P < .001, respectively). The total time in hospital, however, was similar (38 +/- 38 vs. 39 +/- 43 days, P = NS). Three patients had obstruction of the shunt during first hospitalization and 14 patients had a total of 22 obstructions during follow-up. Long-term survival was similar in both groups. The insertion of a titanium tip at the venous end of the LeVeen shunt does not prevent obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)
最近有人提出,在LeVeen分流管的静脉端插入钛制尖端可大幅降低分流管阻塞率。为评估带钛制尖端的LeVeen分流管是否能改善治疗性腹腔穿刺术的效果,81例肝硬化和难治性腹水患者被随机分为腹腔穿刺术加静脉输注白蛋白治疗组(42例)或带钛制尖端的LeVeen分流管治疗组(39例)。如果患者在随访期间因腹水再次入院,第一组患者接受腹腔穿刺术治疗,而LeVeen分流管组患者若证实有阻塞,则通过插入新瓣膜或新分流管进行治疗。在首次住院期间,两种治疗方法在消除腹水方面同样有效。除LeVeen分流管组严重细菌感染率较高外,两组并发症相似。腹腔穿刺术组的平均住院时间比分流管组短。在随访期间,腹腔穿刺术组的再次入院总数和因腹水再次入院的次数均高于分流管组(分别为252次对99次,P <.001;193次对43次,P <.001)。然而,总住院时间相似(38±38天对39±43天,P =无显著性差异)。3例患者在首次住院期间出现分流管阻塞,14例患者在随访期间共出现22次阻塞。两组的长期生存率相似。在LeVeen分流管的静脉端插入钛制尖端并不能防止阻塞。(摘要截短至250字)